New Zealand-based medical device firm Wellumio has launched a subsidiary in California to accelerate US-based clinical trials and commercial rollout of its portable stroke detection device, Axana. The move also signals the company’s closer approach to regulatory approval. The device uses Pulsed Gradient Free Mapping technology to offer insights into the severity and extent of a stroke at the bedside, cutting time taken for detection and treatment.
Startup OMass Secures $310M to Advance Drug for Rare Endocrine Disorder
OMass’s molecule is vying to become an alternative to a Neurocrine Biosciences drug that is currently the only FDA-approved therapy for congenital adrenal hyperplasia. But
